Analyst firms · CLSA · RMD
CLSA RMD price target and rating history
ResMed Inc. (RMD) · Health Care
CLSA rates ResMed Inc. (RMD) Outperform, as of its latest action on Sep 2, 2025. It has published 5 rating actions on RMD since August 2021, including 3 upgrades and 2 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
- Current rating
- Outperform
- Price target
- Not stated
- Median target, all firms
- $235
- Actions on RMD
- 5
Every CLSA rating on RMD
- Sep 2, 2025
- Aug 15, 2022
- Jan 13, 2022
- Oct 22, 2021
- Aug 2, 2021
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about CLSA and RMD
- What is CLSA's rating on RMD?
- CLSA rates RMD Outperform, a bullish rating, as of Sep 2, 2025.
- When did CLSA last change its view on RMD?
- On Sep 2, 2025, CLSA upgrades to Outperform from Hold.
- How does CLSA's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235.
More RMD rating histories
- RBC Capital Markets13
- Citigroup8
- Morgan Stanley4
- Robert W. Baird4
- Wolfe Research3
- Needham3
- J.P. Morgan6
- BofA Securities3
All CLSA ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.